Pathobiology and management of prostate cancer-induced bone pain: Recent insights and future treatments

Inflammopharmacology

Volumn 21, Issue 5, 2013, Pages 339-363

  Muralidharan, Arjun ^a   Smith, Maree T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Analgesics; Bone metastases; Bone pain; Prostate cancer

Indexed keywords

ANALGESIC AGENT; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN 1; ETARACIZUMAB; LEXIDRONAM SAMARIUM SM 153; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ODANACATIB; OPIATE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PHOSPHORUS 32; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; RADIUM 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; SARACATINIB; STRONTIUM 89; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; META ANALYSIS (TOPIC); MOLECULAR INTERACTION; NAUSEA; NOCICEPTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PANCYTOPENIA; PATHOPHYSIOLOGY; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER INDUCED BONE PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RODENT; SENSITIZATION; SIDE EFFECT; SOMATOSENSORY SYSTEM; SPINAL CORD; SPINAL GANGLION; THROMBOCYTOPENIA;

ADJUVANTS, PHARMACEUTIC; ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; NOCICEPTIVE PAIN; PAIN MANAGEMENT; PROSTATIC NEOPLASMS;

EID: 84884813750     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-013-0183-7     Document Type: Review

References (271)

1. Achbarou A, Kaiser S, Tremblay G et al (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54:2372-2377
2. Adwan H, Bauerle TJ, Berger MR (2004) Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11:109-120
3. Agholme F, Li X, Isaksson H et al (2010) Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25:2412-2418
4. Akerley W, Butera J, Wehbe T et al (2002) A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 94:1654-1660
5. Amato RJ, Hernandez-McClain J, Henary H (2008) Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol 31:532-538
6. Antonarakis ES, Heath EI, Posadas EM et al (2013) A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 71:883-892
7. Araujo JC, Poblenz A, Corn P et al (2009) Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther 8:2153-2159
8. Araujo JC, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118:63-71
9. Asim M, Siddiqui IA, Hafeez BB et al (2008) Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 27:3596-3604
10. Aubin JE (1998) Bone stem cells. J Cell Biochem Suppl 30-31:73-82
11. Averill S, Delcroix JD, Michael GJ et al (2001) Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones. Mol Cell Neurosci 18:183-196
12. Baczyk M, Czepczynski R, Milecki P et al (2007) 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28:245-250
13. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171-179
14. Barnes GL, Javed A, Waller SM et al (2003) Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63:2631-2637
15. Basbaum AI, Bautusta DM, Scherrer G et al (2009) Cellular and molecular mechanisms of pain. Cell 139:267-284
16. Bendre MS, Montague DC, Peery T (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28-37
17. Berruti A, Dogliotti L, Gorzegno G et al (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45:1240-1247
18. Bidard FC, Pierga JY, Vincent-Salomon A et al (2008) A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev 27:5-10
19. Bodine PV, Komm BS (2006) Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7:33-39
20. Body JJ, Greipp P, Coleman RE et al (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887-892
21. Bone HG, McClung MR, Roux C et al (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937-947
22. Braz JM, Basbaum AI (2010) Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli. Pain 150:290-301
23. Brownlow N, Mol C, Hayford C et al (2009) Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23:590-594
24. Brubaker KD, Vessella RL, True LD et al (2003) Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18:222-230
25. Buijs JT, Henriquez NV, van Overveld PG et al (2007) TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24:609-617
26. Bussard KM, Gay CV, Mastro AM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27:41-55
27. Campo McKnight DA, Sosnoski DM, Koblinski JE et al (2006) Roles of osteonectin in the migration of breast cancer cells into bone. J Cell Biochem 97:288-302
28. Carducci MA, Nelson JB, Bowling MK et al (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20:2171-2180
29. Carducci MA, Padley RJ, Breul J et al (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-689
30. Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959-1966
31. Casimiro S, Guise TA, Chirgwin J (2009) The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310:71-81
32. Castellano D, Sepulveda JM, Garcia-Escobar I et al (2011) The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 16:136-145
33. Caterina MJ, Leffler A, Malmberg AB et al (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306-313
34. Chang YM, Bai L, Liu S et al (2008) Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27:6365-6375
35. Chen G, Sircar K, Aprikian A et al (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107:289-298
36. Chirgwin JM, Guise TA (2007) Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 102:1333-1342
37. Clare C, Royle D, Saharia K et al (2005) Painful bone metastases: a prospective observational cohort study. Palliat Med 19:521-525
38. Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3(Suppl 3):S131-S139
39. Cleary JF (2007) The pharmacologic management of cancer pain. J Palliat Med 10:1369-1394
40. Clezardin P (2011) Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48:71-79
41. Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7
42. Clines GA, Mohammad KS, Bao Y et al (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21:486-498
43. Clohisy DR, O' Keefe PF, Ramnaraine ML (2001) Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res 19:554-558
44. Clover J, Dodds RA, Gowen M (1992) Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci 103:267-271
45. Cohen P, Peehl DM, Graves HC et al (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142:407-415
46. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s
47. Cramer SD, Chen Z, Peehl DM (1996) Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156:526-531
48. DaSilva J, Gioeli D, Weber MJ et al (2009) The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res 69:7402-7411
49. De Ciantis PD, Yashpal K, Henry J et al (2010) Characterization of a rat model of metastatic prostate cancer bone pain. J Pain Res 3:213-221
50. Desai B, Rogers MJ, Chellaiah MA (2007) Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 6:18
51. Dolezal J, Vizda J, Odrazka K (2007) Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int 78:50-57
52. Donovan-Rodriguez T, Dickenson AH, Urch CE (2004) Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 360:29-32
53. Dougall WC, Glaccum M, Charrier K et al (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424
54. Dovio A, Sartori ML, Masera RG et al (2004) Effects of physiological concentrations of steroid hormones and interleukin-11 on basal and stimulated production of interleukin-8 by human osteoblast-like cells with different functional profiles. Clin Exp Rheumatol 22:79-84
55. Eddleston A, Marenzana M, Moore AR et al (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24:1662-1671
56. Eisenberg E, Berkey CS, Carr DB et al (1994) Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12:2756-2765
57. Eisman JA, Bone HG, Hosking DJ et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242-251
58. Fairchild A, Barnes E, Ghosh S et al (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75:1501-1510
59. ® (dasatinib) Tablet. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021986s7s8lbl.pdf. Accessed 16 Feb 2013
60. Feeley BT, Krenek L, Liu N et al (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38:154-166
61. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
62. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
63. Gordon-Williams RM, Dickenson AH (2007) Central neuronal mechanisms in cancer-induced bone pain. Curr Opin Support Palliat Care 1:6-10
64. Goyal J, Antonarakis ES (2012) Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett 323:135-146
65. Gramoun A, Shorey S, Bashutski JD et al (2007) Effects of vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem 102:341-352
66. Guise TA, Chirgwin JM (2003) Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 415(Suppl):S32-S38
67. Guo W, Wang H, Watanabe M et al (2007) Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 27:6006-6018
68. Hald A, Nedergaard S, Hansen RR et al (2009) Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain 13:138-145
69. Hall DG, Stoica G (1994) Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9:221-230
70. Hall CL, Daignault SD, Shah RB et al (2008) Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68:1396-1404
71. Halvorson KG, Kubota K, Sevcik MA et al (2005) A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65:9426-9435
72. Han JH, Choi SJ, Kurihara N et al (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349-3353
73. Han SH, de Klerk JM, Tan S et al (2002) The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 43:1150-1156
74. Hannon RA, Clack G, Rimmer M et al (2010) Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25:463-471
75. Hattersley G, Owens J, Flanagan AM et al (1991) Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun 177:526-531
76. Hirbe AC, Morgan EA, Weilbaecher KN (2010) The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des 16:1284-1290
77. Holen I, Croucher PI, Hamdy FC et al (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623
78. Honore P, Rogers SD, Schwei MJ et al (2000a) Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585-598
79. Honore P, Schwei J, Rogers SD et al (2000b) Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 129:389-397
80. Horne WC, Neff L, Chatterjee D et al (1992) Osteoclasts express high levels of pp 60c-src in association with intracellular membranes. J Cell Biol 119:1003-1013
81. Huang WC, Xie Z, Konaka H et al (2005) Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65:2303-2313
82. Hudmon A, Choi JS, Tyrrell L et al (2008) Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 28:3190-3201
83. IASP (2009) Pharmacological management of cancer pain. IASP Press, Seattle
84. Ibrahim T, Flamini E, Mercatali L et al (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:1406-1418
85. James ND, Caty A, Borre M et al (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55:1112-1123
86. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
87. Jensen AB, Wynne C, Ramirez G et al (2010) The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 10:452-458
88. Ji RR, Samad TA, Jin SX et al (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68
89. Jimenez-Andrade JM, Bloom AP, Stake JI et al (2010a) Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30:14649-14656
90. Jimenez-Andrade JM, Mantyh WG, Bloom AP et al (2010b) Bone cancer pain. Ann N Y Acad Sci 1198:173-181
91. Jimenez-Andrade JM, Ghilardi JR, Castaneda-Corral G et al (2011) Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 152:2564-2574
92. Jin JK, Dayyani F, Gallick GE (2011) Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128:2545-2561
93. Jung Y, Wang J, Schneider A et al (2006) Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 38:497-508
94. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97:834-839
95. Kasperk CH, Borcsok I, Schairer HU et al (1997) Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 60:368-374
96. Khasabov SG, Hamamoto DT, Harding-Rose C et al (2007) Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain. Brain Res 1180:7-19
97. Kim DS, Figueroa KW, Li KW et al (2009a) Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors. Pain 143:114-122
98. Kim LC, Song L, Haura EB (2009b) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587-595
99. Kingsley LA, Fournier PG, Chirgwin JM et al (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609-2617
100. Knox JD, Cress AE, Clark V et al (1994) Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145:167-174
101. Kohno T, Moore KA, Baba H et al (2003) Peripheral nerve injury alters excitatory synaptic transmission in lamina II of the rat dorsal horn. J Physiol 548:131-138
102. Kolosov A, Aurini L, Williams ED et al (2011) Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Med 12:923-941
103. Koreckij T, Nguyen H, Brown LG et al (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101:263-268
104. Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10:169-180
105. Kryger GS, Kryger Z, Zhang F et al (2001) Nerve growth factor inhibition prevents traumatic neuroma formation in the rat. J Hand Surg Am 26:635-644
106. Kundu N, Yang Q, Dorsey R et al (2001) Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93:681-686
107. Kwan Tat S, Padrines M, Theoleyre S et al (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60
108. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
109. Laird JM, Bennett GJ (1993) An electrophysiological study of dorsal horn neurons in the spinal cord of rats with an experimental peripheral neuropathy. J Neurophysiol 69:2072-2085
110. Lalich M, McNeel DG, Wilding G et al (2007) Endothelin receptor antagonists in cancer therapy. Cancer Invest 25:785-794
111. Lam MG, Dahmane A, Stevens WHBA et al (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35:756-765
112. Lambert B, de Klerk JM (2006) Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 27:223-229
113. Lamoureux F, Ory B, Battaglia S et al (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer 122:751-760
114. Lara PN Jr, Longmate J, Evans CP et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20:179-184
115. Latremoliere A, Woolf CJ (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10:895-926
116. Lee LF, Guan J, Qiu Y et al (2001) Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21:8385-8397
117. Lee LF, Louie MC, Desai SJ et al (2004) Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23:2197-2205
118. Lee RJ, Saylor PJ, Smith MR (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:88-95
119. Leeming DJ, Hegele A, Byrjalsen I et al (2008) Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 17:1269-1276
120. Lemke M, Liena K, Zenga L et al (2012) New considerations in the design of clinical trials for bone metastases. World J Oncol 3:1-7
121. Lewiecki EM (2011) Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 11:117-127
122. Lewington VJ (1996) Cancer therapy using bone-seeking isotopes. Phys Med Biol 41:2027-2042
123. Lewington VJ, McEwan AJ, Ackery DM et al (1991) A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27:954-958
124. Li J, Sarosi I, Yan XQ et al (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571
125. Li X, Ominsky MS, Niu QT et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869
126. Li X, Ominsky MS, Warmington KS et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
127. Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28:623-630
128. Liepe K, Geidel H, Haase M et al (2005) New model for the induction of osteoblastic bone metastases in rat. Anticancer Res 25:1067-1073
129. Lilleby W (2007) Use of bisphosphonates in advanced prostate cancer: current status. Indian J Urol 23:54
130. Lin A, Ray ME (2006) Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 25:669-675
131. Lin T, Li K, Zhang FY et al (2007) Dissociation of spinal microglia morphological activation and peripheral inflammation in inflammatory pain models. J Neuroimmunol 192:40-48
132. Lin C, Jiang X, Dai Z et al (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24:1651-1661
133. Lipton A (2007) Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 4:92-100
134. Lipton A (2010) Bone continuum of cancer. Am J Clin Oncol 33:S1-S7
135. Lipton A, Goessl C (2011) Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48:96-99
136. Littlewood-Evans AJ, Bilbe G, Bowler WB et al (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386-5390
137. Liu FY, Qu XX, Cai J et al (2011) Electrophysiological properties of spinal wide dynamic range neurons in neuropathic pain rats following spinal nerve ligation. Neurosci Bull 27:1-8
138. Lu Y, Chen Q, Corey E et al (2009) Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 26:161-169
139. Luo Y, Zhang LL, Ning L et al (2006) Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145. Zhonghua Nan Ke Xue 12:133-136
140. Luzzi KJ, MacDonald IC, Schmidt EE et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153:865-873
141. Manas A, Casas F, Ciria JP et al (2008) Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol 10:281-287
142. Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7:797-809
143. Mantyh PW, Koltzenburg M, Mendell LM et al (2011) Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115:189-204
144. Marenzana M, Greenslade K, Eddleston A et al (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385-2395
145. Martin SW, Butcher AJ, Berrow NS et al (2006) Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels. Cell Calcium 39:275-292
146. Martin CD, Jimenez-Andrade JM, Ghilardi JR et al (2007) Organization of a unique net-like meshwork of CGRP + sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci Lett 427:148-152
147. McNicol E, Strassels SA, Goudas L et al (2005) NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 25:CD005180
148. McQuay HJ, Collins SL, Carroll D et al (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2:CD001793
149. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1-18
150. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-432
151. Mercadante S, Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19:308-314
152. Millard M, Odde S, Neamati N (2011) Integrin targeted therapeutics. Theranostics 1:154-188
153. Moester MJ, Papapoulos SE, Lowik CW et al (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99-107
154. Mohammad KS, Guise TA (2003) Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res 415:S67-S74
155. Morrissey C, Vessella RL (2007) The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 101:873-886
156. Msaouel P, Pissimissis N, Halapas A et al (2008) Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 22:341-355
157. Mundy GR, Chen D, Zhao M et al (2001) Growth regulatory factors and bone. Rev Endocr Metab Disord 2:105-115
158. Muralidharan A, Wyse BD, Smith MT (2013) Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioural, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol Biochem Behav 106:33-46
159. Naing A, Cohen R, Dy GK et al (2013) A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. doi: 10.1007/s10637-013-9929-8
160. Nakamura I, le Duong T, Rodan SB et al (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25:337-344
161. Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185-9189
162. Nelson JB, Hedican SP, George DJ et al (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949
163. Nelson JB, Nabulsi AA, Vogelzang NJ et al (2003) Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-1149
164. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113:2478-2487
165. Nersesyan H, Slavin KV (2007) Current approach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag 3:381-400
166. Neville-Webbe HL, Cross NA, Eaton CL et al (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86:269-279
167. Nilsson S, Strang P, Aksnes AK et al (2012) A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48:678-686
168. Nilsson S, Sartor O, Oyvind S et al (2013) Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 31(Suppl 6):19
169. Nomiya T, Teruyama K, Wada H et al (2010) Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study. Clin J Pain 26:38-42
170. Okamoto M, Baba H, Goldstein PA et al (2001) Functional reorganization of sensory pathways in the rat spinal dorsal horn following peripheral nerve injury. J Physiol 532:241-250
171. Olson TH, Riedl MS, Vulchanova L et al (1998) An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. NeuroReport 9:1109-1113
172. Oosterhof GO, Roberts JT, de Reijke TM et al (2003) Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44:519-526
173. Opgenorth TJ, Adler AL, Calzadilla SV et al (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481
174. Pagliaro LC, Delpassand ES, Williams D et al (2003) A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97:2988-2994
175. Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358-1365
176. Park SI, Zhang J, Phillips KA et al (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68:3323-3333
177. Parker C, Heinrich D, O'Sullivan JM et al (2012) Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 30(Suppl 5):8
178. Parker CC, Pascoe S, Chodacki A et al (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63:189-197
179. Peleshok JC, Ribeiro-da-Silva A (2011) Delayed reinnervation by nonpeptidergic nociceptive afferents of the glabrous skin of the rat hindpaw in a neuropathic pain model. J Comp Neurol 519:49-63
180. Peters CM, Ghilardi JR, Keyser CP et al (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193:85-100
181. Porter AT, McEwan AJ, Powe JE et al (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813
182. Pratap J, Lian JB, Stein GS (2011) Metastatic bone disease: role of transcription factors and future targets. Bone 48:30-36
183. Proff P, Romer P (2009) The molecular mechanism behind bone remodelling: a review. Clin Oral Investig 13:355-362
184. Quilty PM, Kirk D, Bolger JJ et al (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40
185. Rachner TD, Hadji P, Hofbauer LC (2012) Novel therapies in benign and malignant bone diseases. Pharmacol Ther 134:338-344
186. Rades D, Schild SE, Abrahm JL (2010) Treatment of painful bone metastases. Nat Rev Clin Oncol 7:220-229
187. Raghavendra V, Tanga FY, DeLeo JA (2004) Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 20:467-473
188. Rainville P, Duncan GH, Price DD et al (1997) Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 277:968-971
189. Resche I, Chatal JF, Pecking A et al (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583-1591
190. Robinson RG, Preston DF, Baxter KG et al (1993) Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 20:44-48
191. Robinson DR, Zylstra CR, Williams BO (2008) Wnt signaling and prostate cancer. Curr Drug Targets 9:571-580
192. Rodrigues P, Hering F, Campagnari JC (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7:350-354
193. Roodman GD (2001) Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571
194. Roque IFM, Martinez-Zapata MJ, Scott-Brown M et al (2011) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 7:CD003347
195. Rosenthal MA, Davidson P, Rolland F et al (2010) Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 6:42-48
196. Roudier MP, Haynes K, Feldman R et al (2005) Evaluation of pain in breast and prostate cancer bone metastasis rat models. AACR Meeting Abstracts 2005:684
197. Ruiz G, Ceballos D, Banos JE (2004) Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res 1011:1-6
198. Russell RG, Rogers MJ, Frith JC et al (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 14:53-65
199. Russo A, Bronte G, Rizzo S et al (2010) Anti-endothelin drugs in solid tumors. Expert Opin Emerg Drugs 15:27-40
200. Ryan CW, Vogelzang NJ, Vokes EE et al (2004) Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 10:4406-4411
201. Saad F, Lipton A (2010a) Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr Opin Support Palliat Care 4:127-134
202. Saad F, Lipton A (2010b) SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36:177-184
203. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
204. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
205. Sabino MA, Ghilardi JR, Jongen JL et al (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62:7343-7349
206. Saftig P, Hunziker E, Wehmeyer O et al (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458
207. Sartor O, Reid RH, Hoskin PJ et al (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940-945
208. Saylor PJ, Smith MR (2010) Bone health and prostate cancer. Prostate Cancer Prostatic Dis 13:20-27
209. Saylor PJ, Armstrong AJ, Fizazi K et al (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63:309-320
210. Schelman WR, Liu G, Wilding G et al (2011) A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 29:118-125
211. Schluter KD, Katzer C, Piper HM (2001) A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol 132:427-432
212. Schmidt BL, Hamamoto DT, Simone DA et al (2010) Mechanism of cancer pain. Mol Interv 10:164-178
213. Schneider JG, Amend SR, Weilbaecher KN (2011) Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 48:54-65
214. Scholz J, Broom DC, Youn DH et al (2005) Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 25:7317-7323
215. Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9:S7
216. Schwei MJ, Honore P, Rogers SD et al (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-10897
217. Sciuto R, Festa A, Rea S et al (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79-86
218. Seftor RE, Seftor EA, Gehlsen KR et al (1992) Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89:1557-1561
219. Seibel MJ (2008) The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol (Oxf) 68:839-849
220. Serafini AN, Houston SJ, Resche I et al (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574-1581
221. Sethi N, Kang Y (2011) Dysregulation of developmental pathways in bone metastasis. Bone 48:16-22
222. Sherrington CS (1906) The integrative action of the nervous system. Scribner, New York
223. Simone DA, Khasabov SG, Hamamoto DT (2008) Changes in response properties of nociceptive dorsal horn neurons in a murine model of cancer pain. Sheng Li Xue Bao 60:635-644
224. Small EJ, Smith MR, Seaman JJ et al (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277-4284
225. Smeland S, Erikstein B, Aas M et al (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56:1397-1404
226. Smith MT, Muralidharan A (2013) Pain pharmacology and the pharmacological management of pain. In: Unruh AM, Strong J, Baxter GD (eds) Pain: a textbook for health professionals, chap 11, 2nd edn. Churchill Livingstone, London (in press)
227. Sommer C, Lalonde A, Heckman HM et al (1995) Quantitative neuropathology of a focal nerve injury causing hyperalgesia. J Neuropathol Exp Neurol 54:635-643
228. Sotgiu ML, Biella G, Riva L (1994) A study of early ongoing activity in dorsal horn units following sciatic nerve constriction. NeuroReport 5:2609-2612
229. Sotgiu ML, Biella G, Riva L (1995) Poststimulus afterdischarges of spinal WDR and NS units in rats with chronic nerve constriction. NeuroReport 6:1021-1024
230. Stamboulian S, Choi JS, Ahn HS et al (2010) ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci 30:1637-1647
231. Stoch SA, Zajic S, Stone J et al (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175-182
232. Sumitani K, Kamijo R, Toyoshima T et al (2001) Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30:41-47
233. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337-358
234. Sun YX, Wang J, Shelburne CE et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89:462-473
235. Sun YX, Schneider A, Jung Y et al (2005) Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20:318-329
236. Suzuki R, Kontinen VK, Matthews E et al (2000) Enlargement of the receptive field size to low intensity mechanical stimulation in the rat spinal nerve ligation model of neuropathy. Exp Neurol 163:408-413
237. Sze WM, Shelley MD, Held I et al (2003) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 15:345-352
238. Sze WM, Shelley M, Held I et al (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev 2:CD004721
239. Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832-1837
240. Takahashi N, Udagawa N, Takami M et al (2002) Cells of bone: osteoclast generation. Principles of bone biology, vol 1st. Academic, San Diego
241. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16:2927-2931
242. Tian X, Setterberg RB, Li X et al (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529-533
243. Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 50:893-899
244. Trump DL, Payne H, Miller K et al (2011) Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate 71:1264-1275
245. Tu SM, Lin SH (2008) Current trials using bone-targeting agents in prostate cancer. Cancer J 14:35-39
246. Urch CE, Donovan-Rodriguez T, Dickenson AH (2003) Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 106:347-356
247. Vallejo R, Tilley DM, Vogel L et al (2010) The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract 10:167-184
248. van der Pluijm G, Sijmons B, Vloedgraven H et al (2001) Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 16:1077-1091
249. Vandyke K, Dewar AL, Farrugia AN et al (2009) Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23:994-997
250. Vogel CL, Yanagihara RH, Wood AJ et al (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687-695
251. Walz DA, Fenton JW (1994) The role of thrombin in tumor cell metastasis. Invasion Metastasis 14:303-308
252. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411-425
253. WHO (1986) Cancer pain relief. WHO, Geneva
254. Wilson SR, Peters C, Saftig P et al (2009) Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284:2584-2592
255. Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2:CD002068
256. Wu JS, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594-605
257. Wu JD, Higgins LM, Steinle A et al (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560-568
258. Yanagisawa Y, Furue H, Kawamata T et al (2010) Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Mol Pain 6:38
259. Ye L, Kynaston HG, Jiang WG (2007) Bone metastasis in prostate cancer: molecular and cellular mechanisms (review). Int J Mol Med 20:103-111
260. Yen LD, Bennett GJ, Ribeiro-da-Silva A (2006) Sympathetic sprouting and changes in nociceptive sensory innervation in the glabrous skin of the rat hind paw following partial peripheral nerve injury. J Comp Neurol 495:679-690
261. Yi B, Williams PJ, Niewolna M et al (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62:917-923
262. Yoneda T, Sasaki A, Dunstan C et al (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509-2517
263. Yu E, Wilding G, Posadas E et al (2009) Phase II Study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428
264. Yu E, Massard C, Gross ME et al (2011) Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77:1166-1171
265. Yuen KK, Shelley M, Sze WM et al (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 4:CD006250
266. Zhang JM, Strong JA (2008) Recent evidence for activity-dependent initiation of sympathetic sprouting and neuropathic pain. Sheng Li Xue Bao 60:617-627
267. Zhang RX, Liu B, Wang L et al (2005) Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118:125-136
268. Zhang RX, Liu B, Li A et al (2008a) Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 154:1533-1538
269. Zhang S, Qi L, Li M et al (2008b) Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 27:62
270. Zhang Y, Ma B, Fan Q (2010) Mechanisms of breast cancer bone metastasis. Cancer Lett 292:1-7
271. Zonnenberg BA, Groenewegen G, Janus TJ et al (2003) Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9:2965-2972